Autori: Gastl Guenther A
| Naslov | Pre-treated CML Patients in chronic phase (CP) not achieving at least a major cytogenetic remission (MCyR) after imatinib high dose (HD) induction (800 mg/day, 6 months) are at high risk of progression after dose reduction - Sub-analyses from the CELSG phase III "ISTAHIT" trial (Meeting Abstract) |
| Autori | Petzer Andreas L Fong Dominic Lion Thomas Dyagil Irina Masliak Zvenyslava Bogdanovic Andrija D  Griskevicius Laimonas Lejniece Sandra Goranov Stefan Gercheva Liana Stojanovic Aleksandar Peytchev Dontcho Tzvetkov Nikolay Griniute Rasa Oucheva Radka Grubinger T Kwakkelstein Marthin Rancati Francesca Gastl Guenther A Wolf Dominik
|
| Info | ONKOLOGIE, (2011), vol. 34 br. , Suppl. 6, str. 264-264 |
| Ispravka | Web of Science Elečas Rang časopisa Citati: Web of Science |
     |
| Naslov | High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study (Article) |
| Autori | Petzer Andreas L Wolf Dominik Fong Dominic Lion Thomas Dyagil Irina Masliak Zvenyslava Bogdanovic Andrija D Griskevicius Laimonas Lejniece Sandra Goranov Stefan Gercheva Liana Stojanovic Aleksandar Peytchev Dontcho Tzvetkov Nikolay Griniute Rasa Oucheva Radka Ulmer Hanno Kwakkelstein Marthin Rancati Francesca Gastl Guenther A
|
| Info | HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, (2010), vol. 95 br. 6, str. 908-913 |
| Projekat | Novartis |
| Ispravka | Web of Science Članak Elečas Rang časopisa Citati: Web of Science Scopus |
|
|
| Naslov | High Doses Of Imatinib Mesylate (800mg/Day) Significantly Improve Rates Of Major And Complete Cytogenetic Remissions (Mcr, Ccr) - Results From The First Planned Interim Analysis Of A Multicenter, Randomised, 2-Arm - Phase Iii Study Comparing Imatinib Standard Dose (400 Mg/Day) With Imatinib High Do (Meeting Abstract) |
| Autori | Andreas AP Boskovic Darinka V Gastl Guenther A |
| Info | HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, (2008), vol. 93 br. , Suppl. Suppl. 1, str. 0406- |
| Ispravka | Web of Science Elečas Rang časopisa Citati: Web of Science |
|
|
| Naslov | Celsg Cml 11 "Istahit" Phase Iii Study - Planned Interim Analysis: High Doses Of Imatinib Mesylate (800mg/Day) Significantly Improve Rates Of Major And Complete Cytogenetic Remissions (Mcr, Ccr) In Pretreated Ph+/Bcr-Abl(+) Cml Patients In Chronic Phase (Meeting Abstract) |
| Autori | Petzer Andreas L Boskovic Darinka V Gastl Guenther A |
| Info | BLOOD, (2008), vol. 112 br. 11, str. 406-406 |
| Ispravka | Web of Science Elečas Rang časopisa Citati: Web of Science |
|
|
| Naslov | Multicenter, randomized, phase III study comparing imatinib (Glivec) standard dose (400 mg/d) with imatinib high dose induction (800 mg/d) followed by imatinib maintenance (400 mg/d) in patients with pretreated Ph+/BCR-ABL(+) CML in chronic phase - Results from the first planned interim analysis (CELSG-CML 11 ISTAHIT study) (Meeting Abstract) |
| Autori | Petzer Andreas L Wolf Dominik Fong Dominic Lion Thomas Dyagil Irina Masliak Zvenyslava Boskovic Darinka V Griskevicius Laimonas Lejniece Sandra Spasov Emil Gercheva Liana Stojanovic Aleksandar Peytchev Dontcho Tzvetkov Nikolay Griniute Rasa Stanchev Atanas Kwakkelstein Martin Ulmer Hanno Gastl Guenther A |
| Info | BLOOD, (2007), vol. 110 br. 11, str. 317A-317A |
| Ispravka | Web of Science Elečas Rang časopisa Citati: Web of Science |
|
|
